Abstract : The pediatric AIDS epidemic began in the U
Introduction Human Immunodeficiency
Virus (HIV) is the etiologic agent for the acquired immunodeficiency syndrome (AIDS) epidemic. Early in this epidemic Kaposi's sarcoma was identified in AIDS patients with extremely high frequency, but appeared to be restricted to certain subpopulations.
Specifically this tumor spared hemophilia and pediatric patients with AIDS, indicating some unique environmental risk factors associated with the homosexual AIDS populations, where Kaposi's sarcoma occurs in over 10% of patients (Levine, 1992; Lyter et al., 1995) . Other malignancies also appeared in AIDS patients and included non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (Levine, 1992; Lyter et al., 1995) . The B cell lymphomas were noted in both the adult and pediatric populations and comprised the majority of patients in the latter population (Pizzo, 1995) . Approximately 5% of pediatric and hemophilia AIDS patients developed NHL. Leiomyosarcomas have recently been described with increasing frequency in pediatric patients with AIDS (Jensen et al., 1995; Pizzo, 1995) in contrast to the homosexual population (Lyter et al., 1995) . This review will examine a cohort of these patients and review evidence identifying Epstein-Barr virus (EBV) as a co-factor in these patients.
Methods
In 1985 the South Texas Hemophilia Center tested 108 hemophilia patients less than 21 years of age using standard serologic Western blot techniques for identifying HIV infection. Sixty-nine of these patients were shown to have HIV infection and were clinically followed thru 1996 for the development of malignancy and other AIDS related complications.
The Pediatric Oncology Group began a national epidemiologic study of malignancy in HIV infected patients in 1993 (POG study 9281) and has accumulated data on 24 patients to date (Pollock, et al., 1996) .
We studied six patients with leiomyosarcoma (n = 5) or leiomyoma (n = 1) and HIV infection; and seven patients without HIV infection and leiomyosarcoma (n = 3) or leiomyoma (n = 4) (Jensen, et al., 1995). Tumor tissue samples were immunostained for EBV receptor (CD 21) and pan B cell antigen (CD 20) using mouse monoclonal antibodies (Becton Dickinson, San Jose, California) and Vectiscan Elite ABC-DAB substrate kits (Vector Laboratories, Burlingame, California).
Adequate tumor tissue was available in 2 patients for quantitative PCR and EBV clonality studies. Sections of tumors were prepared on glass slides and hybridized with biotinylated oligonucleotides complementary to three regions of the EBV-EBER-1 (EBER) genes and the HIV gag gene (Jensen, et al., 1995) . EBV clonality studies were evaluated with Southern blot techniques using EcoRII and Xho I terminal probes (Jensen, et al., 1995) . The epidemiologic data for the 24 HIV positive patients with malignancy collected between 1992 and 1996 by the Pediatric Oncology Group is outlined on Table 2 .
The patient data for the 6 patients with leiomyosarcoma or leiomyoma and AIDS is outlined on Table 3 . The histochemical, PCR and clonality results are outlined on Table 4 . Discussion Malignancy was observed in 8% of patients in the pediatric hemophilia population reported here. The majority of these patients had B cell non-Hodgkin's lymphoma (67%). This is comparable to the more than 5% incidence of malignancy observed in a cohort of pediatric HIV infected patients followed by the National Cancer Institute (Pizzo, 1995) . In a larger group of hemophilia patients Ragni et al. (1993) reported a 5.5% incidence of NHL. In the series reported above as well as other pediatric studies, Kaposi's sarcoma was an extremely rare event, in contrast to the greater than 10% incidence reported in the homosexual AIDS population in the United States (Lyter et al., 1995) . These epidemiologic studies indicate that co-factors related to malignancy in AIDS are different or express themselves differently depending on the patient population infected.
Differences in malignancy could not be identified in pediatric patients based on the route of HIV transmission. NHL and leiomyosarcoma have been reported in similar proportions in both vertically and horizontally transmitted cases. The development of malignancy as an AIDS defining event occurs in less than 2% of the pediatric patients. The onset of malignancy generally follows years of infection. In the hemophilia population described here the 1st malignancy was observed in 1989, a minimum of 4 to 5 years after initial HIV infection. As survival in AIDS populations increase it is possible that the incidence of malignancy will comparably increase.
A number of studies have demonstrated or suggested that EBV plays a role in development of non-Hodgkin's and Hodgkin's lymphomas in AIDS patients. Ragni et al. (1993) demonstrated EBV DNA in 36% of lymphoma samples from HIV positive hemophiliacs by in situ hybridization. Shibita et al. (1993) found EBV expression in 39 of 59 (66%) of NHL specimens from AIDS patients. In addition to finding latent EBV nuclear antigen (EBNA-1) transcripts these authors also found EBV latent membrane associated protein, unlike that previously reported for HIV negative patients. In similar studies of Hodgkin's disease, Herndier et al. (1993) and Tirelli et al. (1995) have described a high prevalence of EBV in tumor tissues, including Reed-Sternberg cells. Specifically Tirelli found EBV genome in 78% of Hodgkin's disease associated with HIV infection and 80% of these were associated with a monoclonal genome.
EBV also appears capable of infecting smooth muscle cells. Our studies of leiomyosarcoma in children also demonstrate that EBV is present in tumors from HIV positive patients but not HIV negative patients. Furthermore in two of the six patients studied adequate tissue was available for clonality studies, which demonstrated a Table 4 : Results of tumor immunostaining for the pan-B-cell antigen (CD20) and the EBV receptor (CD21) biclonal and a monoclonal proliferation of genome in these patients. Thus EBV appears to be an important cofactor associated with malignancy in pediatric patients and potentially can contribute to the development of both lymphoid and non-lymphoid tumors.
